Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 Q1- Text added to 2021 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
New words:
alveolar, appeal, argued, atezolizumab, differentiated, dismissed, Enviro, futility, IDMC, instructed, issuer, Maryland, maximum, MFN, monotherapy, motion, NaN, NOL, PD, PK, PR, scan, sixty, substantive, toxicity, tribunal, uliledlimab, underwriting, weekly
Removed:
affinity, Antifolate, automatically, Cadillac, Circuit, circumvent, constant, device, diligent, discussed, display, emergency, Erleada, exercising, globally, insurer, Judge, loosen, mandated, metastatic, mutation, notified, NV, Pharmaceutica, portfolio, Potentiation, preceded, prolongation, QTcF, ready, regain, remanded, repeal, replacement, ruled, upheld, wild, Wuhan, Xtandi
Valuein 2021 Q1 filing- Value in 2021 Q2 filing
Original filings
Filing view